Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of CTI BioPharma patents

List of CTI BioPharma patents

List of RheoSense patents

List of Benefit Cosmetics patents

List of Blackhawk Specialty Tools patents

List of LaunchBox Digital Jun 2009 companies

Electric vehicle venture capital investors

Patents where

Current Assignee

Name

is

CTI BioPharma

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 9573964 Oxygen linked pyrimidine derivatives	Patent 9573964 was granted and assigned to CTI BioPharma on February, 2017 by the United States Patent and Trademark Office.	CTI BioPharma	CTI BioPharma		United States Patent and Trademark Office	9573964	February 21, 2017
	‌ US Patent 10517876 Oxygen linked pyrimidine derivatives	Patent 10517876 was granted and assigned to CTI BioPharma on December, 2019 by the United States Patent and Trademark Office.	CTI BioPharma	CTI BioPharma		United States Patent and Trademark Office	10517876	December 31, 2019
	‌ US Patent 9624242 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt	Patent 9624242 was granted and assigned to CTI BioPharma on April, 2017 by the United States Patent and Trademark Office.	CTI BioPharma	CTI BioPharma		United States Patent and Trademark Office	9624242	April 18, 2017
	‌ US Patent 8980873 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt	Patent 8980873 was granted and assigned to CTI BioPharma on March, 2015 by the United States Patent and Trademark Office.		CTI BioPharma		United States Patent and Trademark Office	8980873	March 17, 2015
	‌ US Patent 8987243 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt	Patent 8987243 was granted and assigned to CTI BioPharma on March, 2015 by the United States Patent and Trademark Office.		CTI BioPharma		United States Patent and Trademark Office	8987243	March 24, 2015
	‌ US Patent 9211262 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity	Patent 9211262 was granted and assigned to CTI BioPharma on December, 2015 by the United States Patent and Trademark Office.		CTI BioPharma		United States Patent and Trademark Office	9211262	December 15, 2015
	‌ US Patent 9062074 (9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt	Patent 9062074 was granted and assigned to CTI BioPharma on June, 2015 by the United States Patent and Trademark Office.		CTI BioPharma		United States Patent and Trademark Office	9062074	June 23, 2015
	‌ US Patent 11135227 Oxygen linked pyrimidine derivatives	Patent 11135227 was granted and assigned to CTI BioPharma on October, 2021 by the United States Patent and Trademark Office.	CTI BioPharma	CTI BioPharma		United States Patent and Trademark Office	11135227	October 5, 2021

8 results

0 selected

8 results

0 selected